Ritalin LA

See also: Generic Ritalin, Generic Ritalin-SR

Ritalin LA is a brand name of methylphenidate, approved by the FDA in the following formulation(s):

RITALIN LA (methylphenidate hydrochloride - capsule, extended release; oral)

• 
  Manufacturer: NOVARTIS
  
  Approval date: June 5, 2002
  
  Strength(s): 20MG ^[AB], 30MG ^[AB], 40MG ^[RLD][AB]

Has a generic version of Ritalin LA been approved?

A generic version of Ritalin LA has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Ritalin LA and have been approved by the FDA:

methylphenidate hydrochloride capsule, extended release; oral

• 
  Manufacturer: ACTAVIS
  
  Approval date: December 1, 2011
  
  Strength(s): 20MG ^[AB], 30MG ^[AB], 40MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ritalin LA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Delivery of multiple doses of medications
  Patent 5,837,284
  Issued: November 17, 1998
  Inventor(s): Mehta; Atul M. & Zeitlin; Andrew L. & Dariani; Maghsoud M.
  Dosage forms for oral administration of a methylphenidate drug are provided. The dosage forms provide a substantially immediate dose of methylphenidate upon ingestion, followed by one or more additional doses at predetermined times. By providing such a drug release profile, the dosage forms eliminate the need for a patient to carry an additional dose for ingestion during the day. The dosage forms and methods provided are useful in administering methylphenidate and pharmaceutically acceptable salts thereof, which generally require one or more doses throughout the day.
  
  Patent expiration dates:
  
  
  • December 4, 2015
    
    ✓ 
    Drug product
  
  



• 
  Multiparticulate modified release composition
  Patent 6,228,398
  Issued: May 8, 2001
  Inventor(s): Devane; John G. & Stark; Paul & Fanning; Niall M. M.
  Assignee(s): Elan Corporation, PLC
  The invention relates to a multiparticulate modified release composition that in operation delivers an active ingredient in a pulsed or bimodal manner. The multiparticulate modified release composition comprises an immediate release component and a modified release component; the immediate release component comprising a first population of active ingredient containing particles and the modified release component compnsimg a second population of active ingredient containing particles coated with a controlled release coating; wherein the combination of the immediate release and modified release components in operation deliver the active ingredient in a pulsed or a bimodal manner. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition. The plasma profile achieved by the multiparticulate modified release composition is advantageous in reducing patient tolerance to the active ingredient and in increasing patient compliance by reducing dosage frequency.
  
  Patent expiration dates:
  
  
  • November 1, 2019
    
    ✓ 
    Patent use: TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES
    ✓ 
    Drug product
  
  



• 
  Delivery of multiple doses of medications
  Patent 6,635,284
  Issued: October 21, 2003
  Inventor(s): Atul M.; Mehta & Andrew L.; Zeitlin & Maghsoud M.; Dariani
  Assignee(s): Celegene Corporation
  Dosage forms for oral administration of a methylphenidate drug are provided. The dosage forms provide a substantially immediate dose of methylphenidate upon ingestion, followed by one or more additional doses at predetermined times. By providing such a drug release profile, the dosage forms eliminate the need for a patient to carry an additional dose for ingestion during the day. The dosage forms and methods provided are useful in administering methylphenidate and pharmaceutically acceptable salts thereof, which generally require one or more doses throughout the day.
  
  Patent expiration dates:
  
  
  • December 4, 2015
    
    ✓ 
    Patent use: TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
    ✓ 
    Drug product
  
  



• 
  Delivery of multiple doses of medications
  Patent 7,431,944
  Issued: October 7, 2008
  Inventor(s): Mehta; Atul M. & Zeitlin; Andrew L. & Dariani; Maghsoud M.
  Assignee(s): Celgene Corporation
  Dosage forms for oral administration of a methylphenidate drug are provided. The dosage forms provide a substantially immediate dose of methylphenidate upon ingestion, followed by one or more additional doses at predetermined times. By providing such a drug release profile, the dosage forms eliminate the need for a patient to carry an additional dose for ingestion during the day. The dosage forms and methods provided are useful in administering methylphenidate and pharmaceutically acceptable salts thereof, which generally require one or more doses throughout the day.
  
  Patent expiration dates:
  
  
  • December 4, 2015
    
    ✓ 
    Drug product
  
  

See also...

• Ritalin LA Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Ritalin LA Consumer Information (Cerner Multum)
• Ritalin LA Advanced Consumer Information (Micromedex)
• Methylphenidate Consumer Information (Drugs.com)
• Methylphenidate Consumer Information (Wolters Kluwer)
• Methylphenidate Chewable Tablets Consumer Information (Wolters Kluwer)
• Methylphenidate Controlled-Release Capsules Consumer Information (Wolters Kluwer)
• Methylphenidate Controlled-Release Tablets Consumer Information (Wolters Kluwer)
• Methylphenidate Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Methylphenidate Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Methylphenidate Solution Consumer Information (Wolters Kluwer)
• Methylphenidate System Consumer Information (Wolters Kluwer)
• Methylphenidate Consumer Information (Cerner Multum)
• Methylphenidate transdermal Consumer Information (Cerner Multum)
• Methylphenidate Oral, Transdermal Advanced Consumer Information (Micromedex)
• Methylphenidate Transdermal Advanced Consumer Information (Micromedex)
• Methylphenidate Hydrochloride AHFS DI Monographs (ASHP)